A psychedelic brief from Rose Hill Life Sciences

Find the signal.

Psychedelic medicine is having its scientific moment. Most coverage cannot tell breakthrough from press release. Every Tuesday, you get the difference, in plain language, with the citations to back it up.

Get the next issue, free
One email per week · Unsubscribe anytime
Latest issue
What most clinical summaries get wrong about psilocybin and PTSD.
8 min read · June 25
Why this exists

The field is loud. We make it legible.

In 2026, more than 1,800 articles will be published about psychedelic medicine. Most will be press releases dressed as journalism. A small fraction will move the science forward. We read everything. We write only about what matters.

How a Tuesday morning works

Three steps. One inbox.

Every issue follows the same arc: observation, evidence, takeaway. The structure is what makes it readable in five minutes and useful for the rest of the week.

Step 01 / Read

We comb 50+ primary sources.

PubMed, ClinicalTrials.gov, FDA filings, EMA notices, conference proceedings, and direct conversations with researchers. So you do not have to.

Step 02 / Filter

We separate signal from noise.

Press releases get cross-checked against trial data. Hot takes get checked against the underlying paper. Hype gets named as such.

Step 03 / Send

Tuesday morning, in your inbox.

500 to 1,000 words. Charts where they help. Citations always. Written so a curious patient and a working researcher both leave with something useful.

Who it's for

Four kinds of readers. One newsletter.

The psychedelic medicine space moves fast and gets reported badly. The Rose Hill Review exists for the readers who cannot afford either problem.

01 / Patients & advocates

For people navigating real conditions.

For people exploring options for treatment-resistant depression, PTSD, stroke recovery, and other conditions, plus the people supporting them. Get clarity on what is available, what is coming, and what is still hype.

02 / Investors & operators

For investors, venture firms, and operators who need reliable signal.

LPs, family offices, VCs, and operators trying to separate credible early-stage opportunities from PR-driven promotion. We name names, cite sources, and flag what is actually moving.

03 / Researchers & clinicians

For researchers and clinicians who need consolidated coverage.

Neuroscientists, psychiatrists, and trial coordinators who want consolidated weekly updates on protocols, outcomes, and regulatory shifts — drawn from primary sources, not secondhand summaries.

04 / Curious public

For people who just want to understand.

Health journalists, policy thinkers, and the genuinely curious. Accessible explainers grounded in primary research. No woo. No moral panic. Just the work.

Recent issues

The latest from Rose Hill Review.

Latest · Clinical Science·Jun 25, 2026

What most clinical summaries get wrong about psilocybin and PTSD.

The neuroplasticity window, decoded, and data from 80 veterans that shows what it looks like in practice.

8 min read
What readers say

From the inboxes of people who'd know.

Researchers, investors, and patients sharing what the Rose Hill Review does for their week.

The only psychedelic newsletter I forward to my entire research team. They do the work of reading the actual papers so we do not have to argue about second-hand summaries.

Principal Investigator
Academic Medical Center

I run a fund focused on this space. The Rose Hill Review is the first thing I read Tuesday morning. It is the only one I trust to flag a press release dressed up as a breakthrough.

Managing Partner
Life Sciences VC

As a veteran exploring trial options, this newsletter cut through more confusion in three issues than six months of forums. Honest, careful, never selling me anything.

U.S. Military Veteran
Reader
Domenic Suppa, editor of the Rose Hill Review
Editor · Rose Hill Review
About

From Rose Hill Life Sciences.

Domenic is the co-founder and Chief Operating Officer of Rose Hill Health Holdings, with 11+ years as a senior executive in operationally complex, highly regulated industries. His path into alternative medicine started in 2010 with a seed investment into Evolab, a Denver-based vertically integrated cannabis company, where he served as COO from 2013 to 2018 through the acquisition by Harvest Health and Recreation (HARV: CSE). He went on to lead manufacturing operations at Supreme Cannabis (CSE: FIRE), supported the BLISSCO acquisition, and has worked with national brands including KKE, Monogram, Native Sun, Terps, and Tilt.

The Rose Hill Review was built because credible science kept getting crowded out by hot takes, and credible companies kept getting conflated with hype factories. Each issue is built from primary sources: peer-reviewed papers, regulatory filings, trial registries, and direct conversations with the researchers and clinicians shaping the field. The goal is not to be the loudest voice in psychedelic medicine. It is to be the one you trust when the next headline drops.

Co-founder, COO
Rose Hill Life Sciences
Industry experience
11+ years operations
Connect
LinkedIn
The Rose Hill Review

One email.
Every Tuesday.
Worth the open.

The next issue ships in five days. Get on the list and start with Vol. 048.